rs587776601
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1_StrongPP5_Very_Strong
The ENST00000246515.2(SLURP1):βc.82delβ(p.Cys28AlafsTer5) variant causes a frameshift change. The variant allele was found at a frequency of 0.0000663 in 1,612,852 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (β β ).
Frequency
Genomes: π 0.000066 ( 0 hom., cov: 33)
Exomes π: 0.000066 ( 0 hom. )
Consequence
SLURP1
ENST00000246515.2 frameshift
ENST00000246515.2 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 3.99
Genes affected
SLURP1 (HGNC:18746): (secreted LY6/PLAUR domain containing 1) The protein encoded by this gene is a member of the Ly6/uPAR family but lacks a GPI-anchoring signal sequence. It is thought that this secreted protein contains antitumor activity. Mutations in this gene have been associated with Mal de Meleda, a rare autosomal recessive skin disorder. This gene maps to the same chromosomal region as several members of the Ly6/uPAR family of glycoprotein receptors. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most 50 bp of the penultimate exon, not predicted to undergo nonsense mediated mRNA decay. There are 17 pathogenic variants in the truncated region.
PP5
Variant 8-142741898-CA-C is Pathogenic according to our data. Variant chr8-142741898-CA-C is described in ClinVar as [Pathogenic]. Clinvar id is 4599.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr8-142741898-CA-C is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SLURP1 | NM_020427.3 | c.82del | p.Cys28AlafsTer5 | frameshift_variant | 2/3 | ENST00000246515.2 | NP_065160.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SLURP1 | ENST00000246515.2 | c.82del | p.Cys28AlafsTer5 | frameshift_variant | 2/3 | 1 | NM_020427.3 | ENSP00000246515 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000657 AC: 10AN: 152182Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
10
AN:
152182
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000321 AC: 8AN: 249290Hom.: 0 AF XY: 0.0000444 AC XY: 6AN XY: 135190
GnomAD3 exomes
AF:
AC:
8
AN:
249290
Hom.:
AF XY:
AC XY:
6
AN XY:
135190
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000664 AC: 97AN: 1460552Hom.: 0 Cov.: 32 AF XY: 0.0000619 AC XY: 45AN XY: 726516
GnomAD4 exome
AF:
AC:
97
AN:
1460552
Hom.:
Cov.:
32
AF XY:
AC XY:
45
AN XY:
726516
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000657 AC: 10AN: 152300Hom.: 0 Cov.: 33 AF XY: 0.0000134 AC XY: 1AN XY: 74468
GnomAD4 genome
AF:
AC:
10
AN:
152300
Hom.:
Cov.:
33
AF XY:
AC XY:
1
AN XY:
74468
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 25, 2023 | ClinVar contains an entry for this variant (Variation ID: 4599). This premature translational stop signal has been observed in individual(s) with Mal de Meleda (PMID: 11285253, 24093092). This variant is present in population databases (rs587776601, gnomAD 0.008%). This sequence change creates a premature translational stop signal (p.Cys28Alafs*5) in the SLURP1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SLURP1 are known to be pathogenic (PMID: 11285253, 19692209). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 03, 2018 | The c.82delT pathogenic variant in the SLURP1 gene has been reported previously in the homozygous state in multiple unrelated individuals with Mal de Maleda (Fischer et al., 2001; Charfeddine et al., 2003). The c.82delT variant causes a frameshift starting with codon Cysteine 28, changes this amino acid to an Alanine residue, and creates a premature Stop codon at position 5 of the new reading frame, denoted p.Cys28AlafsX5. This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The c.82delT variant is observed in 10/126,090 (0.008%) alleles from individuals of non-Finnish European background in large population cohorts (Lek et al., 2016). We interpret c.82delT as a pathogenic variant. - |
Acroerythrokeratoderma Pathogenic:2
Pathogenic, no assertion criteria provided | literature only | OMIM | Mar 01, 2004 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Mar 28, 2018 | The SLURP1 c.82delT (p.Cys28AlafsTer5) variant results in a frameshift and is predicted to result in premature termination of the protein. Across a selection of the literature, the p.Cys28AlafsTer5 variant has been reported in a homozygous state in a total of 15 individuals affected with mal de Meleda from eight families (Charfeddine et al. 2003; Ward et al. 2003; Bchetnia et al. 2013; Bergqvist et al. 2018). Both Charfeddine et al. (2003) and Ward et al. (2003) demonstrated that the parents of the affected individuals carried the variant in a heterozygous state. Additionally, Fischer et al. (2001) identified the p.Cys28AlafsTer5 variant in a homozygous state in an unknown number of affected individuals from 15 families. Two female obligate carriers of the p.Cys28AlafsTer5 variant were shown to have attenuated signs of skin disease (Mokni et al. 2004). Favre et al. (2007) demonstrated that the sweat of one individual with the p.Cys28AlafsTer5 variant showed an absence of SLURP1. The p.Cys28AlafsTer5 variant was absent from 200 Palestinian controls, but is reported at a frequency of 0.000079 in the European (non-Finnish) population of the Genome Aggregation Database. Based on the evidence and potential impact of frameshift variants, the p.Cys28AlafsTer5 variant is classified as pathogenic for mal de Meleda. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at